The secondary endpoint was to evaluate the prognostic value of Krebs von den Lungen-6 (KL-6) in the disease progression in IPF patients using the baseline KL-6 value and the change in KL-6 values between the baseline and 12 months.<h4>Results</h4>A total of 44 patients were enrolled, of whom 39 completed the study, with 13 patients assigned to each of the three groups. This evidence concerns the gene MUC1 and idiopathic pulmonary fibrosis.